Acalabrutinib-Venetoclax With or Without Obinutuzumab Significantly Prolongs PFS in Fit Patients with Previously Untreated CLL By Ogkologos - February 25, 2025 570 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the AMPLIFY study Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR How to Talk to Your Kids About Ways to Prevent Cancer July 26, 2022 Can Cancer Prevention Be Better Integrated into Primary Care? June 5, 2023 Long-Term Survival in a Significant Proportion of Patients with a 1p/19q... June 28, 2022 Breast Cancer Survivor Fights Back After Instagram Bans Photos of Her... February 5, 2020 Load more HOT NEWS Cancer in My Community: Overcoming Inequities in Care in Argentina Breastfeeding Duration Could Influence Breast Cancer Risk, Study Shows Registered Dietitian vs. Nutritionist New Low-Powered Implantable Device Monitors Soft Tissue for Signs of Breast...
